Lexicon Pharmaceuticals (LXRX) has reported notable findings from the SOTA-INS CGM Phase 3 Randomized Clinical Trial. The data indicate that a once-daily dose of 400 mg sotagliflozin significantly improves time-in-range and various continuous glucose monitoring metrics, including glucose variability, in patients with type 2 diabetes who are undergoing insulin treatment. Furthermore, the trial observed positive trends with a 200 mg once-daily dose of the medication.Craig Granowitz, Lexicon’s Senior Vice President and Chief Medical Officer, commented: “While we are not seeking approval to treat type 2 diabetes per se, this study enhances the body of evidence underscoring the incremental benefits of SGLT1 inhibition.”The material has been provided by InstaForex Company – www.instaforex.com
- Philippines’ FX Reserves Climb to $112 Billion in September - October 7, 2024
- Czech Republic’s Trade Balance Swings to Surplus in August 2024 - October 7, 2024
- Czech Republic’s Industrial Production Rebounds with 1.5% Growth in August 2024 - October 7, 2024
